Skip to content

Psilocybin: all studies

Page 183 of 440: studies 1,821 to 1,830 of 4,392, newest first. Back to the psilocybin overview

Research

Preparation of Monoclonal Antibodies Reactive to a Hallucinogenic Drug, Psilocin

JOURNAL OF HEALTH SCIENCE 2004 Mitsune Yamaguchi, Toshiaki Saito, Yoshie Horiguchi et al. 5 citations

The cultivation or trafficking of “Magic mushrooms,” containing hallucinogenic psilocin and psilocybin, has been prohibited by the Narcotics and Psychotropics Control Law in Japan since 2002. To identify these mushrooms, we attempted to prepare the monoclonal antibody (mAb) reactive to these hallucinogens. As an antigen inducing an anti-psilocin mAb,...

DOI: 10.1248/jhs.50.600 (opens in new tab) Psilocybin Monoclonal antibody Hallucinogen Keyhole limpet hemocyanin +3

Morphological and chemical analysis of magic mushrooms in Japan.

Forensic Science International December 17, 2003 Kenji Tsujikawa, Tatsuyuki Kanamori, Yuko T Iwata et al. 79 citations

Morphological and toxicological analyses were performed on hallucinogenic mushrooms that are currently circulated in Japan. Scanning electron microscope (SEM) indicated a three-dimensional microstructures in the mushrooms. The complementary use of SEM with an optical microscope was effective for observing characteristic tissues, such as basidiomycetes, spores, cystidia and basidia....

Concise Large-Scale Synthesis of Psilocin and Psilocybin, Principal Hallucinogenic Constituents of “Magic Mushroom”

Journal of Natural Products May 30, 2003 Osamu Shirota, Wataru Hakamata, Yukihiro Goda 90 citations

The concise large-scale syntheses of psilocin (1) and psilocybin (2), the principal hallucinogenic constituents of "magic mushroom", were achieved without chromatographic purification. The key step in the synthesis of 2 was the isolation of the dibenzyl-protected intermediate (7) as a zwitterionic derivative (8), which was completely identified by means of 2D NMR analyses.

DOI: 10.1021/np030059u (opens in new tab) Psilocybin Hallucinogen Mushroom Stereochemistry

The Analysis of Psilocybin and Psilocin from Fungi

Analytical techniques in the sciences March 28, 2003 Michael D. Cole 3 citations

This chapter contains sections titled: Introduction Identification of Psilocybin- and Psilocin-containing Mushrooms Identification of Fungal Species from Morphological Characteristics Identification of Psilocin and Psilocybin Using Chemical Analysis Quantification of Psilocin and Psilocybin by HPLC The Identification of Psilocybin- and Psilocin-containing Fungi Using DNA Profiling References

DOI: 10.1002/0470868007.ch8 (opens in new tab) Psilocybin Identification biology Hallucinogen Chromatography

Effects of the 5-HT2A Agonist Psilocybin on Mismatch Negativity Generation and AX-Continuous Performance Task: Implications for the Neuropharmacology of Cognitive Deficits in Schizophrenia

Neuropsychopharmacology 2003 Daniel Umbricht, Franz X. Vollenweider, Liselotte Schmid et al. 192 citations

Previously the NMDA (N-methyl-D-aspartate) receptor (NMDAR) antagonist ketamine was shown to disrupt generation of the auditory event-related potential (ERP) mismatch negativity (MMN) and the performance of an 'AX'-type continuous performance test (AX-CPT)--measures of auditory and visual context-dependent information processing--in a similar manner as observed in schizophrenia. This...

DOI: 10.1038/sj.npp.1300005 (opens in new tab) Full text (opens in new tab) Psilocybin Mismatch negativity Nmda receptor Schizophrenia object-oriented programming +5

Psilocybin Fast Facts

PsycEXTRA Dataset 2003

This DOI is not currently attached to any metadata records. DOIs can’t actually ever be deleted (they’re persistent), but sometimes our members create DOIs in error. We do have a process to approximate deletion which we follow only in rare cases where the DOI has been genuinely created in error, and most crucially, if the DOI has never been published anywhere online or in print and never...

Discrimination of Psychoactive Fungi (Commonly Called "Magic Mushrooms") Based on the DNA Sequence of the Internal Transcribed Spacer Region.

Food Hygiene and Safety Science (Shokuhin Eiseigaku Zasshi) 2003 Takuro Maruyama, Osamu Shirota, Nobuo Kawahara et al. 14 citations

'Magic mushrooms' (MMs) are psychoactive fungi containing the hallucinogenic compounds, psilocin (1) and psilocybin (2). Since June 6, 2002, these fungi have been regulated by the Narcotics and Psychotropics Control Law in Japan. Because there are many kinds of MMs and they are sold even as dry powders in local markets, it is very difficult to identify the original species of the MMs by...

DOI: 10.3358/shokueishi.44.44 (opens in new tab) Internal transcribed spacer Sequence biology Genetics

The pharmacology of psilocybin

Addiction Biology October 1, 2002 Torsten Passie, Juergen Seifert, Udo Schneider et al. 465 citations

Abstract Psilocybin (4‐phosphoryloxy‐N,N‐dimethyltryptamine) is the major psychoactive alkaloid of some species of mushrooms distributed worldwide.These mushrooms represent a growing problem regarding hallucinogenic drug abuse. Despite its experimental medical use in the 1960s, only very few pharmacological data about psilocybin were known until recently. Because of its still growing capacity...

Synthesis of a psilocin hapten and a protein-hapten conjugate

Journal of Pharmacy and Pharmacology September 1, 2002 Christian Albers, Matthias Lehr, Justus Beike et al. 7 citations

Abstract Derivatives of psilocin with ω-functionalized alkyl spacers in position 1 of the indole ring were synthesized as haptens for use in a radioimmunoassay. Whereas the psilocin analogues with a 3-aminopropyl and a 4-aminobutyl moiety at the indole nitrogen decomposed during synthesis, the analogous 3-carboxypropyl psilocin derivative proved to be stable. This compound was coupled to bovine...

Renal excretion profiles of psilocin following oral administration of psilocybin: a controlled study in man

Journal of Pharmaceutical and Biomedical Analysis August 26, 2002 Felix Hasler, Daniel Bourquin, Rudolf Brenneisen et al. 100 citations

In a clinical study eight volunteers received psilocybin (PY) in psychoactive oral doses of 212+/-25 microg/kg body weight. To investigate the elimination kinetics of psilocin (PI), the first metabolite of PY, urine was collected for 24 h and PI concentrations were determined by high-performance liquid chromatography with column switching and electrochemical detection (HPLC-ECD). Sample workup...